Cardiff Oncology, Inc. (CRDF)
| Market Cap | 271.33M |
| Revenue (ttm) | 395,656 |
| Net Income (ttm) | -23.05M |
| Shares Out | 38.76M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537,161 |
| Open | 6.61 |
| Previous Close | 6.86 |
| Day's Range | 6.47 - 6.86 |
| 52-Week Range | 4.88 - 25.50 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 25.33 (+283.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zyti...
Financial Performance
In 2020, CRDF's revenue was $365,993, an increase of 49.61% compared to the previous year's $244,632. Losses were -$19.31 million, 17.6% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is 25.33, which is an increase of 283.79% from the latest price.
News
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...
Why Shares of Cardiff Oncology Rose on Monday
An insider buy and positive data may have boosted optimism.
Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?
Cardiff Oncology Inc (NASDAQ: CRDF) has announced new data from Phase 1b/2 evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic c...
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust...
SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- 8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evaluable for disease response as of the dat...
Cardiff Oncology to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on Septe...
SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications w...
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D.
SAN DIEGO, July 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
SAN DIEGO, June 28, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...
Smoked! How the Hottest Cannabis Stocks Fared This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5...
SAN DIEGO, June 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference
SAN DIEGO, May 20, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and -4.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
SAN DIEGO, May 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treat...
Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Let's Take A Look At This Weeks Top Performing Sectors 4/28
Using sector -based investment strategies can help you capitalize on changing business cycles. So far this week the Energy Minerals, Finance, Health services, Transportation, and Commercial Services Sec...
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients
Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal c...